The Case of Synthroid (B) Case Solution And Analysis, HBR Case Study Solution & Analysis of Harvard Case Studies

The case tells the story of Synthroid from its growth in 1958 as the very first synthetic thyroxine molecule to its opposition against generic correspondents in year 2004. The case commences scholars to the pharmaceutical business, its practices, and a number of the complexities of pricing and medicine choice, with insurance companies, drug makers physicians, pharmacists, and patients all playing a part. In addition, it provides a primer on its symptoms hypothyroidism, and its particular treatment. Drug standards of identity were fully confirmed and because Synthroid introduced and was developed before FDA regulations, it was challenging for challengers to get their drugs certified identical to Synthroid. Through a series of efforts with doctors, particularly endocrinologists, the owners of Synthroid could keep the awareness for forty-six years that Synthroid was uniquely effective.

In 2004, however the FDA declared several products that were competitive to be bioequivalent to Synthroid, which introduced a significant challenge to its owner, Abbott Laboratories. Pupils are challenged to consider options to keep the drug's unit quantity, earnings, and/or gain in these challenging conditions. The case is composed in two parts. The (B) case describes what Abbott really did to keep its share in America and summarizes its approach in India, a market devoid of any patent defense for the pharmaceuticals.

The Case of Synthroid (B) case study solution

PUBLICATION DATE: February 19, 2013 PRODUCT #: KEL729-HCB-ENG

This is just an excerpt. This case is about SALES & MARKETING